PDF(Pubmed)
Abstract：
OBJECTIVE: To compare the efficacy and safety of seven Chinese patent medicines (CPMs) combined with conventional triple/quadruple therapy (T/Q) for Helicobacter pylori-positive peptic ulcers.
METHODS: A systematic review and network meta-analysis.
METHODS: China National Knowledge Infrastructure, VIP database, Wanfang database, ScienceDirect, EBSCO, EMBASE, Web of Science, Cochrane Library and PubMed were searched through 1 June 2022.
METHODS: Randomised controlled trials (RCTs) testing CPMs combined with T/Q for H. pylori-positive peptic ulcers were included. The CPMs included Anweiyang capsule, Jianweiyuyang tablets/capsule/granule, Jinghuaweikang capsule, Kangfuxin liquid, Puyuanhewei capsule, Weifuchun tablets/capsule and Weisu granule. At least one of the following outcome indicators was recorded: complete ulcer healing rate (CUHR), effective rate (ER), H. pylori eradication rate (HPER), rate of peptic ulcer recurrence (RPUR) and incidence of adverse reactions (IAR).
METHODS: Two researchers independently conducted the study selection and extracted data for included studies. The risk of bias was assessed using the Cochrane risk of bias tool. A pairwise meta-analysis was performed using RevMan V.5.3. Network meta-analysis was performed using STATA/MP V.15.0. Confidence in the evidence was assessed using Grading of Recommendations, Assessment, Development and Evaluation.
RESULTS: A total of 36 RCTs involving 3620 patients were included. Compared with T/Q alone, Weisu+T/Q, Weifuchun+T/Q and Puyuanhewei+T/Q had the highest CUHR, ER and HPER, respectively. Weisu+T/Q and Jianweiyuyang+T/Q had the lowest RPUR and IAR, respectively. The cluster analysis results showed Jianweiyuyang+T/Q might be the best choice concerning efficacy and safety simultaneously, followed by Kangfuxin+T/Q.
CONCLUSIONS: Among the combination therapies with the CPMs, Jianweiyuyang+T/Q might be the most favourable option for H. pylori-positive peptic ulcers, followed by Kangfuxin+T/Q. Considering the limited quantity and quality of the included RCTs, the results should be interpreted with caution.
UNASSIGNED: CRD42022327687.
METHODS: A systematic review and network meta-analysis.
METHODS: China National Knowledge Infrastructure, VIP database, Wanfang database, ScienceDirect, EBSCO, EMBASE, Web of Science, Cochrane Library and PubMed were searched through 1 June 2022.
METHODS: Randomised controlled trials (RCTs) testing CPMs combined with T/Q for H. pylori-positive peptic ulcers were included. The CPMs included Anweiyang capsule, Jianweiyuyang tablets/capsule/granule, Jinghuaweikang capsule, Kangfuxin liquid, Puyuanhewei capsule, Weifuchun tablets/capsule and Weisu granule. At least one of the following outcome indicators was recorded: complete ulcer healing rate (CUHR), effective rate (ER), H. pylori eradication rate (HPER), rate of peptic ulcer recurrence (RPUR) and incidence of adverse reactions (IAR).
METHODS: Two researchers independently conducted the study selection and extracted data for included studies. The risk of bias was assessed using the Cochrane risk of bias tool. A pairwise meta-analysis was performed using RevMan V.5.3. Network meta-analysis was performed using STATA/MP V.15.0. Confidence in the evidence was assessed using Grading of Recommendations, Assessment, Development and Evaluation.
RESULTS: A total of 36 RCTs involving 3620 patients were included. Compared with T/Q alone, Weisu+T/Q, Weifuchun+T/Q and Puyuanhewei+T/Q had the highest CUHR, ER and HPER, respectively. Weisu+T/Q and Jianweiyuyang+T/Q had the lowest RPUR and IAR, respectively. The cluster analysis results showed Jianweiyuyang+T/Q might be the best choice concerning efficacy and safety simultaneously, followed by Kangfuxin+T/Q.
CONCLUSIONS: Among the combination therapies with the CPMs, Jianweiyuyang+T/Q might be the most favourable option for H. pylori-positive peptic ulcers, followed by Kangfuxin+T/Q. Considering the limited quantity and quality of the included RCTs, the results should be interpreted with caution.
UNASSIGNED: CRD42022327687.
摘要：
目的：比较7种中成药(CPM)联合常规三联/四联疗法(T/Q)治疗幽门螺杆菌阳性消化性溃疡的疗效和安全性。
方法：系统综述和网络荟萃分析。
方法：中国国家知识基础设施，VIP数据库,万方数据库，ScienceDirect,EBSCO,EMBASE,WebofScience,搜索了Cochrane图书馆和PubMed，直到2022年6月1日。
方法：纳入了CPM联合T/Q治疗幽门螺杆菌阳性消化性溃疡的随机对照试验（RCT）。CPM包括安胃阳胶囊，健胃愈阳片/胶囊/颗粒，京华胃康胶囊,康复新液,蒲元和胃胶囊,胃复春片/胶囊、胃素颗粒。至少记录以下结果指标之一：完全溃疡愈合率（CUHR），有效率（ER），幽门螺杆菌根除率（HPER），消化性溃疡复发率(RPUR)和不良反应发生率(IAR)。
方法：两名研究人员独立进行研究选择并提取纳入研究的数据。使用Cochrane偏差风险工具评估偏差风险。使用RevManV.5.3进行成对荟萃分析。使用STATA/MPV.15.0进行网络荟萃分析。对证据的信心是使用建议分级评估的，评估,发展和评价。
结果：共纳入36个RCTs，涉及3620例患者。与单独的T/Q相比，Weisu+T/Q,魏富春+T/Q和普源和微+T/Q的CUHR最高，ER和HPER,分别。WeisuT/Q和JisweiyuyangT/Q的RPUR和IAR最低，分别。聚类分析结果表明，健胃愈阳+T/Q可能是同时考虑疗效和安全性的最佳选择。其次是康复新+T/Q.
结论：在与CPM的联合治疗中，健胃育阳+T/Q可能是幽门螺杆菌阳性消化性溃疡的最有利选择，其次是康复新+T/Q.考虑到纳入RCT的数量和质量有限，结果应谨慎解释.
■CRD42022327687。
方法：系统综述和网络荟萃分析。
方法：中国国家知识基础设施，VIP数据库,万方数据库，ScienceDirect,EBSCO,EMBASE,WebofScience,搜索了Cochrane图书馆和PubMed，直到2022年6月1日。
方法：纳入了CPM联合T/Q治疗幽门螺杆菌阳性消化性溃疡的随机对照试验（RCT）。CPM包括安胃阳胶囊，健胃愈阳片/胶囊/颗粒，京华胃康胶囊,康复新液,蒲元和胃胶囊,胃复春片/胶囊、胃素颗粒。至少记录以下结果指标之一：完全溃疡愈合率（CUHR），有效率（ER），幽门螺杆菌根除率（HPER），消化性溃疡复发率(RPUR)和不良反应发生率(IAR)。
方法：两名研究人员独立进行研究选择并提取纳入研究的数据。使用Cochrane偏差风险工具评估偏差风险。使用RevManV.5.3进行成对荟萃分析。使用STATA/MPV.15.0进行网络荟萃分析。对证据的信心是使用建议分级评估的，评估,发展和评价。
结果：共纳入36个RCTs，涉及3620例患者。与单独的T/Q相比，Weisu+T/Q,魏富春+T/Q和普源和微+T/Q的CUHR最高，ER和HPER,分别。WeisuT/Q和JisweiyuyangT/Q的RPUR和IAR最低，分别。聚类分析结果表明，健胃愈阳+T/Q可能是同时考虑疗效和安全性的最佳选择。其次是康复新+T/Q.
结论：在与CPM的联合治疗中，健胃育阳+T/Q可能是幽门螺杆菌阳性消化性溃疡的最有利选择，其次是康复新+T/Q.考虑到纳入RCT的数量和质量有限，结果应谨慎解释.
■CRD42022327687。
